Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies

被引：0
|
作者：
Felten, Renaud [1 ]
Widawski, Laura [2 ]
Spielman, Lionel [2 ]
Gottenberg, Jacques-Eric [3 ]
Duret, Pierre-Marie [2 ]
Rampakakis, Emmanouil [4 ]
Sharaf, Mohamed [5 ]
Constantin, Caren [6 ]
Campana, Vincenza [6 ]
Messer, Laurent [7 ]
机构：
[1] Hop Hautepierre, Strasbourg, France
[2] Hop Civils Colmar, Colmar, France
[3] Strasbourg Univ Hosp, Rheumatol Dept, Strasbourg, France
[4] JSS Med Res, St Laurent, PQ, Canada
[5] Janssen MEA, Immunol, Dubai, U Arab Emirates
[6] Janssen Cilag Med Affairs, Issy Les Moulineaux, France
[7] Lab Interdisciplinaire Etud Culturelles LinCS, Strasbourg, France
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2241
引用
收藏
页码：4429 / 4432
页数：4
相关论文
共 50 条
  • [1] Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
    Deodhar, Atul
    Gottlieb, Alice B.
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Zhuang, Yanli
    Barchuk, William
    Xu, Xie L.
    Hsia, Elizabeth C.
    [J]. LANCET, 2018, 391 (10136): : 2213 - 2224
  • [2] Longitudinal Effect of Guselkumab on Biomarkers of Inflammation and Cardiovascular Risk in Bionaive Patients with Active Psoriatic Arthritis and High Systemic Inflammatory Burden: Post-hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-Controlled Study
    Kavanaugh, Arthur
    Soriano, Enrique
    Dutz, Jan
    Selmi, Carlo
    Rampakakis, Emmanouil
    Shiff, Natalie
    Nantel, Francois
    Lavie, Frederic
    Coates, Laura
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4421 - 4424
  • [3] Impact of Psoriatic Arthritis Manifestations on Perception of Pain Improvement: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies with Guselkumab
    Nash, Peter
    McInnes, Iain
    Ritchlin, Christopher T.
    Tam, Lai-Shan
    Soriano, Enrique
    Starr, Michael
    Rampakakis, Emmanouil
    Lavie, Frederic
    Shawi, May
    Baraliakos, Xenofon
    Mease, Philip J.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2785 - 2787
  • [4] SERUM EXTRACELLULAR MATRIX BIOMARKERS IDENTIFY RESPONSE TO GUSELKUMAB IN PSORIATIC ARTHRITIS: POST-HOC ANALYSIS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS
    Nielsen, S. Holm
    Bay-Jensen, A. C.
    Frederiksen, P.
    Karsdal, M.
    Shawi, M.
    Chakravarty, S. D.
    Kollmeier, A.
    Chen, W.
    Gao, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 342 - 343
  • [5] Serum Extracellular Matrix Biomarkers Identify Response to Guselkumab in Psoriatic Arthritis; Post-hoc Analysis from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
    Nielsen, Signe Holm
    Bay-Jensen, Anne-Christine
    Frederiksen, Peder
    Karsdal, Morten
    Shawi, May
    Chakravarty, Soumya
    Kollmeier, Alexa
    Chen, Warner
    Gao, Sheng
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4219 - 4220
  • [6] Efficacy of ixekizumab in patients with psoriatic arthritis: Results of a phase 3 randomized, double-blind, active- and placebo-controlled study
    Mease, Philip
    van der Heijde, Desiree
    Ritchlin, Christopher
    Cuchacovich, Rachel
    Shuler, Catherine
    Lin, Chen-Yen
    Vangerow, Harald
    Samanta, Suvajit
    Lee, Chin
    Gladman, Dafna
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB248 - AB248
  • [7] Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post-Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
    Ritchlin, Christopher T.
    Mease, Philip J.
    Boehncke, Wolf-Henning
    Tesser, John
    Chakravarty, Soumya D.
    Rampakakis, Emmanouil
    Shawi, May
    Merola, Joseph F.
    McInnes, Iain B.
    Deodhar, Atul
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB225 - AB225
  • [8] Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
    Coates, Laura C.
    Gossec, Laure
    Zimmermann, Miriam
    Shawi, May
    Rampakakis, Emmanouil
    Shiff, Natalie J.
    Kollmeier, Alexa P.
    Xu, Xie L.
    Nash, Peter
    Mease, Philip J.
    Helliwell, Philip S.
    [J]. RMD OPEN, 2024, 10 (01):
  • [9] Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
    Coates, Laura C.
    Rahman, Proton
    Mease, Philip J.
    Shawi, May
    Rampakakis, Emmanouil
    Kollmeier, Alexa P.
    Xu, Xie L.
    Chakravarty, Soumya D.
    McInnes, Iain B.
    Tam, Lai-Shan
    [J]. BMC RHEUMATOLOGY, 2024, 8 (01)
  • [10] Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
    Laura C. Coates
    Proton Rahman
    Philip J. Mease
    May Shawi
    Emmanouil Rampakakis
    Alexa P. Kollmeier
    Xie L. Xu
    Soumya D. Chakravarty
    Iain B. McInnes
    Lai-Shan Tam
    [J]. BMC Rheumatology, 8
12345